Irena Brunskole Hummel1, Anita Zitzmann2, Monika Erl3, Jürgen J Wenzel4, Wolfgang Jilg5. 1. Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany. Electronic address: irena.hummel@klinik.uni-regensburg.de. 2. Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany. Electronic address: anita-zitzmann@t-online.de. 3. Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany. Electronic address: monika.erl@klinik.uni-regensburg.de. 4. Institute of Clinical Microbiology and Hygiene, University Medical Centre Regensburg, 93053 Regensburg, Germany. Electronic address: juergen.wenzel@klinik.uni-regensburg.de. 5. Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany. Electronic address: wolfgang.jilg@klinik.uni-regensburg.de.
Abstract
BACKGROUND AND AIMS: The definition of immune memory after hepatitis B vaccination is still under debate. Therefore, we analysed hepatitis B surface antigen (HBsAg)-specific memory in more detail by investigating the kinetics of humoral and cellular responses after hepatitis B booster vaccination. METHODS: The anti-HBs kinetics of 23 individuals with anti-HBs titres below 10 IU/l, who had been vaccinated 10-15 years ago, was monitored at day 0, 3, 7, 14 and 28 after booster vaccination. HBsAg-specific IFNγ- and IL5-secreting cells in enriched CD4(+) fraction were measured at day 0, 7 and 28 post-booster by enzyme-linked immunospot assay (ELISpot). RESULTS: 22 of 23 subjects showed similar anti-HBs kinetic curves, including 3 of 4 subjects who did not reach anti-HBs titres of 10 IU/l. The steep anti-HBs increase started between day 3 and 7 and peaked around day 14. A plateau or only minimal changes were visible between day 14 and 28. 17.4% of subjects showed pre-booster cellular responses, and this rate had increased to 47.8% and 56.5% after 7 and 28 days, respectively. The kinetic patterns of T cell responses differed considerably among subjects. A dominance of Th2 responses (IL5 secretion) over Th1 responses (IFNγ secretion) could be observed. CONCLUSIONS: The presence of B cell memory could be shown by a typical anamnestic anti-HBs response curve after a booster dose in all but one individual. In contrast, T cell responses to booster vaccination, which occurred in approximately 50% of participants, were rather heterogeneous.
BACKGROUND AND AIMS: The definition of immune memory after hepatitis B vaccination is still under debate. Therefore, we analysed hepatitis B surface antigen (HBsAg)-specific memory in more detail by investigating the kinetics of humoral and cellular responses after hepatitis B booster vaccination. METHODS: The anti-HBs kinetics of 23 individuals with anti-HBs titres below 10 IU/l, who had been vaccinated 10-15 years ago, was monitored at day 0, 3, 7, 14 and 28 after booster vaccination. HBsAg-specific IFNγ- and IL5-secreting cells in enriched CD4(+) fraction were measured at day 0, 7 and 28 post-booster by enzyme-linked immunospot assay (ELISpot). RESULTS: 22 of 23 subjects showed similar anti-HBs kinetic curves, including 3 of 4 subjects who did not reach anti-HBs titres of 10 IU/l. The steep anti-HBs increase started between day 3 and 7 and peaked around day 14. A plateau or only minimal changes were visible between day 14 and 28. 17.4% of subjects showed pre-booster cellular responses, and this rate had increased to 47.8% and 56.5% after 7 and 28 days, respectively. The kinetic patterns of T cell responses differed considerably among subjects. A dominance of Th2 responses (IL5 secretion) over Th1 responses (IFNγ secretion) could be observed. CONCLUSIONS: The presence of B cell memory could be shown by a typical anamnestic anti-HBs response curve after a booster dose in all but one individual. In contrast, T cell responses to booster vaccination, which occurred in approximately 50% of participants, were rather heterogeneous.
Authors: Sylvia M Kiertscher; Pallavi R Gangalum; Grace Ibrahim; Donald P Tashkin; Michael D Roth Journal: J Neuroimmune Pharmacol Date: 2018-01-16 Impact factor: 4.147
Authors: Pierre Van Damme; Marc Dionne; Geert Leroux-Roels; Olivier Van Der Meeren; Emmanuel Di Paolo; Bruno Salaun; Pemmaraju Surya Kiran; Nicolas Folschweiller Journal: J Viral Hepat Date: 2019-06-02 Impact factor: 3.728